S&P 500   3,977.74 (+0.17%)
DOW   32,453.99 (+0.67%)
QQQ   309.01 (-0.60%)
AAPL   158.67 (-0.99%)
MSFT   276.70 (-1.38%)
META   202.87 (-1.52%)
GOOGL   102.90 (-2.41%)
AMZN   97.58 (-0.56%)
TSLA   192.71 (+1.21%)
NVDA   265.29 (-0.93%)
NIO   8.93 (-1.54%)
BABA   85.69 (-1.39%)
AMD   96.27 (-1.72%)
T   18.87 (+1.40%)
F   11.54 (+0.26%)
MU   59.74 (-2.32%)
CGC   1.90 (-0.26%)
GE   92.97 (+1.75%)
DIS   95.03 (+1.01%)
AMC   4.36 (-2.46%)
PYPL   73.32 (-0.76%)
PFE   40.34 (-0.12%)
NFLX   328.46 (+0.02%)
S&P 500   3,977.74 (+0.17%)
DOW   32,453.99 (+0.67%)
QQQ   309.01 (-0.60%)
AAPL   158.67 (-0.99%)
MSFT   276.70 (-1.38%)
META   202.87 (-1.52%)
GOOGL   102.90 (-2.41%)
AMZN   97.58 (-0.56%)
TSLA   192.71 (+1.21%)
NVDA   265.29 (-0.93%)
NIO   8.93 (-1.54%)
BABA   85.69 (-1.39%)
AMD   96.27 (-1.72%)
T   18.87 (+1.40%)
F   11.54 (+0.26%)
MU   59.74 (-2.32%)
CGC   1.90 (-0.26%)
GE   92.97 (+1.75%)
DIS   95.03 (+1.01%)
AMC   4.36 (-2.46%)
PYPL   73.32 (-0.76%)
PFE   40.34 (-0.12%)
NFLX   328.46 (+0.02%)
S&P 500   3,977.74 (+0.17%)
DOW   32,453.99 (+0.67%)
QQQ   309.01 (-0.60%)
AAPL   158.67 (-0.99%)
MSFT   276.70 (-1.38%)
META   202.87 (-1.52%)
GOOGL   102.90 (-2.41%)
AMZN   97.58 (-0.56%)
TSLA   192.71 (+1.21%)
NVDA   265.29 (-0.93%)
NIO   8.93 (-1.54%)
BABA   85.69 (-1.39%)
AMD   96.27 (-1.72%)
T   18.87 (+1.40%)
F   11.54 (+0.26%)
MU   59.74 (-2.32%)
CGC   1.90 (-0.26%)
GE   92.97 (+1.75%)
DIS   95.03 (+1.01%)
AMC   4.36 (-2.46%)
PYPL   73.32 (-0.76%)
PFE   40.34 (-0.12%)
NFLX   328.46 (+0.02%)
S&P 500   3,977.74 (+0.17%)
DOW   32,453.99 (+0.67%)
QQQ   309.01 (-0.60%)
AAPL   158.67 (-0.99%)
MSFT   276.70 (-1.38%)
META   202.87 (-1.52%)
GOOGL   102.90 (-2.41%)
AMZN   97.58 (-0.56%)
TSLA   192.71 (+1.21%)
NVDA   265.29 (-0.93%)
NIO   8.93 (-1.54%)
BABA   85.69 (-1.39%)
AMD   96.27 (-1.72%)
T   18.87 (+1.40%)
F   11.54 (+0.26%)
MU   59.74 (-2.32%)
CGC   1.90 (-0.26%)
GE   92.97 (+1.75%)
DIS   95.03 (+1.01%)
AMC   4.36 (-2.46%)
PYPL   73.32 (-0.76%)
PFE   40.34 (-0.12%)
NFLX   328.46 (+0.02%)
NASDAQ:NBIX

Neurocrine Biosciences - NBIX Stock Forecast, Price & News

$96.26
-0.79 (-0.81%)
(As of 03/27/2023 12:27 PM ET)
Add
Compare
Today's Range
$95.78
$97.30
50-Day Range
$94.11
$111.36
52-Week Range
$75.25
$129.29
Volume
209,271 shs
Average Volume
828,373 shs
Market Capitalization
$9.30 billion
P/E Ratio
62.92
Dividend Yield
N/A
Price Target
$125.65

Neurocrine Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
30.5% Upside
$125.65 Price Target
Short Interest
Healthy
2.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
1.15mentions of Neurocrine Biosciences in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$39.03 M Bought Last Quarter
Proj. Earnings Growth
70.76%
From $2.77 to $4.73 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.19 out of 5 stars

Medical Sector

9th out of 995 stocks

Biological Products, Except Diagnostic Industry

2nd out of 166 stocks


NBIX stock logo

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops, and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Stock News Headlines

Citigroup Sticks to Its Buy Rating for Neurocrine (NBIX)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Analyst Expectations for Neurocrine Biosciences's Future
First Week of NBIX April 21st Options Trading
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
Neurocrine Biosciences Q4 2022 Earnings Preview
Neurocrine Biosciences Earnings Preview
See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Company Calendar

Last Earnings
2/06/2023
Today
3/27/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$125.65
High Stock Price Forecast
$150.00
Low Stock Price Forecast
$95.00
Forecasted Upside/Downside
+29.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
15 Analysts

Profitability

Net Income
$154.50 million
Pretax Margin
14.37%

Debt

Sales & Book Value

Annual Sales
$1.49 billion
Cash Flow
$1.78 per share
Book Value
$17.76 per share

Miscellaneous

Free Float
92,338,000
Market Cap
$9.37 billion
Optionable
Optionable
Beta
0.50

Key Executives

  • Kevin Charles GormanKevin Charles Gorman
    Chief Executive Officer & Director
  • Bill Wilson
    Vice President-Information Technology & Operations
  • Matthew C. Abernethy
    Chief Financial Officer
  • Dimitri E. GrigoriadisDimitri E. Grigoriadis
    Chief Research Officer
  • Eiry W. RobertsEiry W. Roberts
    Chief Medical Officer













NBIX Stock - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NBIX shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price forecast for 2023?

15 analysts have issued 1 year price objectives for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $95.00 to $150.00. On average, they predict the company's stock price to reach $125.65 in the next year. This suggests a possible upside of 29.5% from the stock's current price.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2023?

Neurocrine Biosciences' stock was trading at $119.44 at the start of the year. Since then, NBIX stock has decreased by 18.7% and is now trading at $97.05.
View the best growth stocks for 2023 here
.

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our NBIX earnings forecast
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its earnings results on Monday, February, 6th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.15 by $0.09. The company earned $412 million during the quarter, compared to analysts' expectations of $408.96 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 10.19% and a net margin of 10.38%. Neurocrine Biosciences's revenue was up 32.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.08) EPS.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (2.26%), Avidity Partners Management LP (1.85%), Renaissance Technologies LLC (1.68%), Price T Rowe Associates Inc. MD (1.48%), Geode Capital Management LLC (1.44%) and Brown Advisory Inc. (1.10%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends
.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $97.05.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $9.37 billion and generates $1.49 billion in revenue each year. The company earns $154.50 million in net income (profit) each year or $1.53 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

The company employs 1,200 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.

This page (NASDAQ:NBIX) was last updated on 3/27/2023 by MarketBeat.com Staff